Rovida Advisors’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Rovida Advisors’s Portfolio RVLP Stock Details RVLP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,000,000	Closed	-$1.68M	–	20
2023 Q2	$1.68M	Hold	3,000,000	–	–	0.73%	17
2023 Q1	$3.42M	Hold	3,000,000	–	–	1.33%	15
2022 Q4	$3.24M	Hold	3,000,000	–	–	1.19%	20
2022 Q3	$6.3M	Hold	3,000,000	–	–	2.93%	10
2022 Q2	$4.02M	Hold	3,000,000	–	–	1.03%	18
2022 Q1	$5.07M	Hold	3,000,000	–	–	1.09%	23
2021 Q4	$3.21M	Buy	3,000,000 +2,436,447	+432%	+$3.95M	0.14%	42
2021 Q3	$1.66M	Buy	563,553 +263,245	+88%	+$885K	0.07%	45
2021 Q2	$901K	Buy	+300,308	New	+$919K	0.04%	42

Other funds holding RVLP

ACM

Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

TAM

Titleist Asset Management San Antonio, Texas $1.49B AUM 22.27% 1-Year Est. Return

Rovida Advisors's RVLP Position: Q3 2023 in Review

Rovida Advisors sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q3 2023, closing a stake of 3,000,000 shares — an estimated $1.68M sold.

Rovida Advisors first reported a position in RVLP in Q2 2021 and held it in 9 quarters. The position peaked at $6.3M in Q3 2022. 32 funds tracked by Wall St. Rank hold RVLP as of Q3 2023.

Rovida Advisors reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q3 2023 after selling out during the quarter.
Rovida Advisors sold 3,000,000 RVL Pharmaceuticals plc Ordinary Shares shares in Q3 2023, an estimated $1.68M.
Rovida Advisors first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q2 2021 and held it in 9 quarters.
Rovida Advisors's RVL Pharmaceuticals plc Ordinary Shares position peaked at $6.3M in Q3 2022.
32 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q3 2023.

Based on Rovida Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.